SCHEMBL4331514

SCHEMBL4331514

N#Cc1ccc(C(=O)c2sc(Nc3ccc(N4CCC(N5CCCC(O)C5)CC4)cc3)nc2N)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 3/20 0.57
GSK3B P49841 3/20 0.57
CDK4 P11802 10/20 0.52
CCND1 P24385 10/20 0.52
CDK11A Q9UQ88 8/20 0.52
CCNT1 O60563 8/20 0.52
CDK9 P50750 8/20 0.52
CDK6 Q00534 8/20 0.52
CCNA2 P20248 5/20 0.51
CDK2 P24941 5/20 0.51
NPC1 O15118 3/20 0.44
CDK5 Q00535 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LTK P29376 1/20 0.44
CLK2 P49760 1/20 0.44
CDK7 P50613 1/20 0.44
LIMK1 P53667 1/20 0.44
PRKCQ Q04759 1/20 0.44
TAOK1 Q7L7X3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336187 0.92 GSK3A (0.63) GSK3AGSK3BCDK4CCND1CDK11A
SCHEMBL4331367 0.91 GSK3A (0.62) GSK3AGSK3BCDK4CCND1CDK11A
SCHEMBL4337149 0.91 CDK4 (0.52) GSK3AGSK3BCDK4CCND1CDK11A
SCHEMBL4342717 0.90 CDK4 (0.57) GSK3AGSK3BCDK4CCND1CDK11A
SCHEMBL4335185 0.90 CDK4 (0.55) GSK3AGSK3BCDK4CCND1CDK11A
SCHEMBL4336027 0.90 CDK4 (0.54) GSK3AGSK3BCDK4CCND1CDK11A
SCHEMBL4336196 0.90 CCNA2 (0.55) GSK3AGSK3BCDK4CCND1CDK11A
SCHEMBL4342199 0.87 CCNA2 (0.56) GSK3AGSK3BCDK4CCND1CDK11A
SCHEMBL4331555 0.86 CDK4 (0.51) GSK3AGSK3BCDK4CCND1CDK11A
SCHEMBL4333612 0.86 CDK4 (0.51) GSK3AGSK3BCDK4CCND1CDK11A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740576-B1 NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES HOFFMANN LA ROCHE (CH) 2009-07-01 EP claimed
US-7211576-B2 Diaminothiazoles HOFFMANN-LA ROCHE INC. (US) 2007-05-01 US claimed
US-20050239843-A1 Diaminothiazoles DING QINGJIE 2005-10-27 US claimed
EP-1740576-B1 NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES HOFFMANN LA ROCHE (CH) 2009-07-01 EP disclosed
US-7211576-B2 Diaminothiazoles HOFFMANN-LA ROCHE INC. (US) 2007-05-01 US disclosed
US-7211576-B2 Diaminothiazoles HOFFMANN-LA ROCHE INC. (US) 2007-05-01 US disclosed
US-7211576-B2 Diaminothiazoles HOFFMANN-LA ROCHE INC. (US) 2007-05-01 US disclosed
US-20050239843-A1 Diaminothiazoles DING QINGJIE 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239843-A1 Diaminothiazoles CDK4, CDK2, CDK1 GSK3A 680/4885GSK3B 633/4885CDK4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.